Epizyme announces plans to price initial public sale of common stock

Offering's proceeds used for phase 1 clinical development of EPZ-5676

By Devika Patel

Knoxville, Tenn., April 18 - Epizyme, Inc. will price an initial public offering of its common stock, according to a Form S-1 filed Thursday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "EPZM."

The deal will have a greenshoe option.

Citigroup Global Markets Inc., Cowen and Co., LLC, Leerink Swann LLC, JMP Securities LLC and Wedbush Securities Inc. are assisting.

Proceeds will be used for phase 1 clinical development of EPZ-5676, development costs, research and development, working capital and general corporate purposes.

The biopharmaceutical company is based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.